Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). New 35,090-square-foot Boston headquarters at 10 St. James Avenue.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New 35,090-square-foot Boston headquarters at 10 St. James Avenue
- Base rent $105,279 monthly, payable nine months after commencement
- Lease term ends September 30, 2028, subject to earlier termination
- $210,540 security deposit paid, creating near-term cash use
- Commencement requires full execution of landlord and overlandlord consent
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.